Medindia

X

EarlySense Named Among Israel's Fastest-Growing Companies on 2016 Deloitte Technology Fast 50 List

Tuesday, November 29, 2016 Corporate News J E 4
Advertisement
Inclusion in International Bellwether Ranking Indicative of EarlySense's Global Business Growth

RAMAT GAN, Israel, November 29, 2016 /PRNewswire/ --

EarlySense, the market leader in contact-free continuous monitoring solutions, announced today that it has been named a "Deloitte 2016 Technology Fast 50" company. The annual program recognizes the 50 fastest growing technology companies in Israel, based on growth percentage during the last four years. Fueled by growing sales in the United States, Europe and Asia, EarlySense had a Composite Annual Growth Rate (CAGR) of 163% in revenue during that period.

"Companies on the Technology Fast 50 list not only understand the global market but are able to adapt to inevitable changes that occur in such a disruptive and fast-paced environment," said Shally Tshuva Technology, Media & Telecommunications Industry Leader at Deloitte Israel.  "EarlySense's accelerated growth over the last four years demonstrates the need for their advanced sensing and analytics platform in hospitals, nursing homes as well as at home."

EarlySense's clinically proven contact-free health monitoring solutions are used in medical facilities around the world. In addition, EarlySense has successful medical solution partnerships with Welch Allyn and Herman Miller-Nemschoff.

The company has also adapted its medical technology for consumer home use, further accelerating its growth. EarlySense technology powers Samsung's SleepSense, Beurer's SE 80 SleepExpert, the iFit Sleep Sensor, and Verlo's SmartWake. The company is also set launch its own home Digital Health solution in 2017.

EarlySense's technology uses a unique wireless sensor placed under a mattress to monitor and track patient heart rate, respiratory rate and movement. The solution assists healthcare professionals in early detection of potentially serious events, enabling improved care for patients while providing important financial benefits for facilities.

"Our global growth is the product of years of clinical research focused on providing highly accurate, real-time healthcare data that enables clinicians to achieve direct measurable improvements," said Avner Halperin, CEO of EarlySense.  "Our products cater to the entire continuum of healthcare - hospitals, nursing homes, rehab facilities, as well as people at home. EarlySense will continue to be widely adopted to help improve patient outcomes, save hospitals money, and enable families to care for their loved ones at home, as we bring the power of digital health to every household."

About EarlySense 

EarlySense provides contact-free, continuous monitoring solutions for the medical and consumer digital health markets. EarlySense's patented sensor and advanced algorithms monitor and analyze cardiac, respiratory, sleep and motion parameters. Used in hospitals and healthcare facilities worldwide, EarlySense assists clinicians in early detection of patient deterioration, helping to prevent adverse events, including code blues, preventable ICU transfers, patient falls and pressure ulcers.

The myEarlySense smart home-compatible consumer solution brings hospital-proven technology to the home, providing valuable data regarding wellness and sleep. myEarlySense OEM technology is at the core of wellness and sleep products marketed by international partners including Samsung, Beurer and iFit. EarlySense was founded in 2004 and has offices in Waltham, MA, and Ramat Gan, Israel.

For more information, please visit http://www.EarlySense.com and http://www.myEarlySense.com. 

Follow EarlySense onLinkedIn, Twitter and Facebook.

Media Contact: Ellie Hanson Finn Partners +1-929-222-8006 ellie.hanson@finnpartners.com Company Contact: Hila Peleg +972-54-527-3117 hila.peleg@earlysense.com

SOURCE EarlySense

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Immunohistochemistry Market Worth 2.12 Billion USD...
S
Platelet-Rich Plasma Market Worth US$451.9 Million...